Literature DB >> 25942512

Evolution of anti-IgE treatment.

Cristoforo Incorvaia1, Marina Mauro2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 25942512      PMCID： PMC4856804          DOI： 10.1038/cmi.2015.14

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN： 1672-7681            Impact factor:   11.530


× No keyword cloud information.
  9 in total

1.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Authors:  Marcus Maurer; Karin Rosén; Hsin-Ju Hsieh; Sarbjit Saini; Clive Grattan; Ana Gimenéz-Arnau; Sunil Agarwal; Ramona Doyle; Janice Canvin; Allen Kaplan; Thomas Casale
Journal:  N Engl J Med       Date:  2013-02-24       Impact factor: 91.245

2.  Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control.

Authors:  M Molimard; L Mala; I Bourdeix; V Le Gros
Journal:  Respir Med       Date:  2014-02-12       Impact factor: 3.415

Review 3.  Omalizumab for asthma in adults and children.

Authors:  Rebecca Normansell; Samantha Walker; Stephen J Milan; E Haydn Walters; Parameswaran Nair
Journal:  Cochrane Database Syst Rev       Date:  2014-01-13

Review 4.  Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders.

Authors:  E S Schulman
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

Review 5.  Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.

Authors:  G Norman; R Faria; F Paton; A Llewellyn; D Fox; S Palmer; I Clifton; J Paton; N Woolacott; C McKenna
Journal:  Health Technol Assess       Date:  2013-11       Impact factor: 4.014

Review 6.  The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria.

Authors:  Tse Wen Chang; Christina Chen; Chien-Jen Lin; Martin Metz; Martin K Church; Marcus Maurer
Journal:  J Allergy Clin Immunol       Date:  2014-06-17       Impact factor: 10.793

7.  After 6 years with Xolair; a 3-year withdrawal follow-up.

Authors:  Anna Nopp; S G O Johansson; J Adédoyin; J Ankerst; M Palmqvist; H Oman
Journal:  Allergy       Date:  2009-10-01       Impact factor: 13.146

8.  Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.

Authors:  Andrew C Nyborg; Anna Zacco; Rachel Ettinger; M Jack Borrok; Jie Zhu; Tom Martin; Rob Woods; Christine Kiefer; Michael A Bowen; E Suzanne Cohen; Ronald Herbst; Herren Wu; Steven Coats
Journal:  Cell Mol Immunol       Date:  2015-03-23       Impact factor: 11.530

9.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.